Device-associated infection rates, bacterial resistance, length of stay, and mortality in Kuwait: International Nosocomial Infection Consortium findings

American Journal of Infection Control
Haifaa Hassan Al-MousaSuga Thomas Varghese

Abstract

To report the results of the International Infection Control Consortium (INICC) study conducted in Kuwait from November 2013-March 2015. A device-associated health care-acquired infection (DA-HAI) prospective surveillance study in 7 adult, pediatric, and neonatal intensive care units (ICUs) using the U.S. Centers for Disease Control and Prevention's (CDC's) National Healthcare Safety Network (NHSN) definitions and INICC methods. We followed 3,732 adult and pediatric patients for 21,611 bed days and 671 neonatal patients for 4,515 bed days. In the medical-surgical ICUs, the central line-associated bloodstream infection (CLABSI) rate was 3.5 per 1,000 central line days, the ventilator-associated pneumonia (VAP) rate was 4.0 per 1,000 mechanical ventilator days, and the catheter-associated urinary tract infection (CAUTI) rate was 3.3 per 1,000 urinary catheter days; all of them were lower than INICC rates (CLABSI: 4.9; VAP: 16.5; and CAUTI: 5.3) and higher than NHSN rates (CLABSI: 0.9; VAP: 1.1; and CAUTI: 1.2). Resistance of Staphylococcus aureus to oxacillin was 100%, resistance of Acinetobacter baumannii to imipenem and meropenem was 77.6%, and resistance of Klebsiella pneumoniae to imipenem and meropenem was 29.4%. Extra lengt...Continue Reading

References

Oct 18, 2006·Annals of Internal Medicine·Victor D RosenthalUNKNOWN International Nosocomial Infection Control Consortium
Aug 8, 2008·Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre·Nasser Yehia A AlyEl Sayed M Al Asar
Oct 30, 2010·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Victor D RosenthalUNKNOWN International Nosocomial Infection Control Consortium Investigators
Dec 12, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dawn M SievertUNKNOWN National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities
Jan 8, 2013·Journal of Infection and Public Health·Mona F SalamaVincent O Rotimi
May 9, 2013·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Victor D RosenthalUNKNOWN International Nosocomial Infection Control Consortiuma
Jan 13, 2015·American Journal of Infection Control·Margaret A DudeckDawn M Sievert

❮ Previous
Next ❯

Citations

Aug 11, 2018·Critical Care Medicine·Mari TakashimaAmanda Ullman
May 29, 2018·Journal of Epidemiology and Global Health·Eiman GaidWeam Banjar
Jun 24, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·Shu-Dao XiongZhi-Min Zhai
May 2, 2018·Antimicrobial Resistance and Infection Control·Dmitriy VidermanAzliyati Azizan
Sep 29, 2019·Neurocritical Care·Yasser B AbulhasanEiman M Mokaddas
May 24, 2019·BioMed Research International·Huixue JiaMeilian Chen
Jun 4, 2019·Frontiers in Pediatrics·Margarita Torres-GarcíaDaniela de la Rosa-Zamboni
Dec 29, 2020·American Journal of Infection Control·Mustafa Gokhan GozelEmine Alp Mese
Feb 14, 2021·Materials Science & Engineering. C, Materials for Biological Applications·Hawraa ShahrourGuillermo Martínez-de-Tejada
Oct 9, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Adel AlothmanSouha S Kanj

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.